Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Lima | Healthcare | Pharmaceuticals | PEN 2.49T | 62.1x | 0.74 | PEN 2,664.13 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Lima | Healthcare | Pharmaceuticals | PEN 1.34T | 17x | -0.42 | PEN 564.63 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Lima | Healthcare | Pharmaceuticals | PEN 1.20T | 80x | -2.6 | PEN 685.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Lima | Healthcare | Pharmaceuticals | PEN 713.72B | 11.4x | 0.02 | PEN 278.22 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Lima | Healthcare | Pharmaceuticals | PEN 559.74B | 26x | 0.47 | PEN 958.42 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Lima | Healthcare | Pharmaceuticals | PEN 492.80B | 22.8x | 0.02 | PEN 399.04 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Lima | Healthcare | Pharmaceuticals | PEN 483.19B | 16.8x | 0.01 | PEN 84.69 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Lima | Healthcare | Pharmaceuticals | PEN 355.08B | 18x | 0.1 | PEN 176 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |